Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 149

1.

Mapping heterogeneity in glucose uptake in metastatic melanoma using quantitative 18F-FDG PET/CT analysis.

de Heer EC, Brouwers AH, Boellaard R, Sluiter WJ, Diercks GFH, Hospers GAP, de Vries EGE, Jalving M.

EJNMMI Res. 2018 Nov 20;8(1):101. doi: 10.1186/s13550-018-0453-x.

2.

Preoperative BRAF inhibition in patients with irresectable locally advanced stage III melanoma.

Faut M, Jalving M, Diercks GF, Hospers GA, van Leeuwen BL, Been LB.

Melanoma Manag. 2018 May 16;5(2):MMT08. doi: 10.2217/mmt-2018-0002. eCollection 2018 Jun.

3.

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer.

Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M.

BMC Cancer. 2018 Sep 10;18(1):877. doi: 10.1186/s12885-018-4770-2.

4.

[Recent treatment results for metastatic melanoma: data from the Dutch Melanoma Treatment Registry].

van Zeijl MCT, van den Eertwegh AJM, Wouters MWJM, Jochems A, Schouwenburg MG, Haanen JBAG, Aarts MJ, van den Berkmortel FWPJ, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, van der Veldt AAM, Vreugdenhil G, van der Hoeven KJM.

Ned Tijdschr Geneeskd. 2018 Jun 15;162. pii: D2420. Dutch.

PMID:
30040270
5.

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.

Schouwenburg MG, Jochems A, Leeneman B, Franken MG, van den Eertwegh AJM, Haanen JBAG, van Zeijl MCT, Aarts MJ, van Akkooi ACJ, van den Berkmortel FWPJ, Blokx WAM, de Groot JWB, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van der Hoeven JJM.

Melanoma Res. 2018 Aug;28(4):326-332. doi: 10.1097/CMR.0000000000000453.

PMID:
29750749
6.

Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands.

Jochems A, Leeneman B, Franken MG, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, Groenewegen G, de Groot JWB, Haanen JBAG, Hospers GAP, Kapiteijn E, Koornstra RH, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, Uyl-de Groot CA, van der Hoeven KJM.

Anticancer Drugs. 2018 Jul;29(6):572-578. doi: 10.1097/CAD.0000000000000629.

PMID:
29659371
7.

Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands.

Franken MG, Leeneman B, Jochems A, Schouwenburg MG, Aarts MJB, van Akkooi ACJ, van den Berkmortel FWPJ, van den Eertwegh AJM, de Groot JWB, van der Hoeven KJM, Hospers GAP, Kapiteijn E, Koornstra R, Kruit WHJ, Louwman MWJ, Piersma D, van Rijn RS, Suijkerbuijk KPM, Ten Tije AJ, Vreugdenhil G, Wouters MWJM, van Zeijl M, Haanen JBAG, Uyl-de Groot CA.

Anticancer Drugs. 2018 Jul;29(6):579-588. doi: 10.1097/CAD.0000000000000628.

PMID:
29634490
8.

18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients.

Nienhuis HH, van Kruchten M, Elias SG, Glaudemans AWJM, de Vries EFJ, Bongaerts AHH, Schröder CP, de Vries EGE, Hospers GAP.

J Nucl Med. 2018 Aug;59(8):1212-1218. doi: 10.2967/jnumed.117.198846. Epub 2018 Mar 30.

PMID:
29602822
9.

Enhanced expression of PD-1 and other activation markers by CD4+ T cells of young but not old patients with metastatic melanoma.

van den Brom RRH, van der Geest KSM, Brouwer E, Hospers GAP, Boots AMH.

Cancer Immunol Immunother. 2018 Jun;67(6):925-933. doi: 10.1007/s00262-018-2148-6. Epub 2018 Mar 15.

10.

Checks and Balances in Autoimmune Vasculitis.

Hid Cadena R, Abdulahad WH, Hospers GAP, Wind TT, Boots AMH, Heeringa P, Brouwer E.

Front Immunol. 2018 Feb 22;9:315. doi: 10.3389/fimmu.2018.00315. eCollection 2018.

11.

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.

Bisschop C, Ter Elst A, Bosman LJ, Platteel I, Jalving M, van den Berg A, Diepstra A, van Hemel B, Diercks GFH, Hospers GAP, Schuuring E.

Melanoma Res. 2018 Apr;28(2):96-104. doi: 10.1097/CMR.0000000000000421.

12.

Systemic vasculitis developed after immune checkpoint inhibition: comment on the article by Cappelli et al.

Rutgers A, van den Brom RRH, Hospers GAP, Heeringa P, Brouwer E.

Arthritis Care Res (Hoboken). 2018 Aug;70(8):1275. doi: 10.1002/acr.23481. No abstract available.

PMID:
29195007
13.

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.

Noordman BJ, Verdam MGE, Lagarde SM, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch OR, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A, Sprangers MAG, van Lanschot JJB.

J Clin Oncol. 2018 Jan 20;36(3):268-275. doi: 10.1200/JCO.2017.73.7718. Epub 2017 Nov 21.

PMID:
29161204
14.

Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.

Venema CM, Mammatas LH, Schröder CP, van Kruchten M, Apollonio G, Glaudemans AWJM, Bongaerts AHH, Hoekstra OS, Verheul HMW, Boven E, van der Vegt B, de Vries EFJ, de Vries EGE, Boellaard R, Menke van der Houven van Oordt CW, Hospers GAP.

J Nucl Med. 2017 Dec;58(12):1906-1912. doi: 10.2967/jnumed.117.193649. Epub 2017 Sep 14.

15.

In Vivo Quantification of ERβ Expression by Pharmacokinetic Modeling: Studies with 18F-FHNP PET.

Antunes IF, Willemsen ATM, Sijbesma JWA, Boerema AS, van Waarde A, Glaudemans AWJM, Dierckx RAJO, de Vries EGE, Hospers GAP, de Vries EFJ.

J Nucl Med. 2017 Nov;58(11):1743-1748. doi: 10.2967/jnumed.117.192666. Epub 2017 Jul 13.

16.

Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study.

Bisschop C, van Dijk TH, Beukema JC, Jansen RLH, Gelderblom H, de Jong KP, Rutten HJT, van de Velde CJH, Wiggers T, Havenga K, Hospers GAP.

Ann Surg Oncol. 2017 Sep;24(9):2632-2638. doi: 10.1245/s10434-017-5897-0. Epub 2017 May 30.

17.

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

Blank CU, Larkin J, Arance AM, Hauschild A, Queirolo P, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Garbe C, Chiarion Sileni V, Mandalà M, Gogas H, Espinosa E, Hospers GAP, Miller WH Jr, Robson S, Makrutzki M, Antic V, Brown MP.

Eur J Cancer. 2017 Jul;79:176-184. doi: 10.1016/j.ejca.2017.04.007. Epub 2017 May 11.

PMID:
28501764
18.

Effect of Extending the Original Eligibility Criteria for the CROSS Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.

de Heer EC, Hulshoff JB, Klerk D, Burgerhof JGM, de Groot DJA, Plukker JTM, Hospers GAP.

Ann Surg Oncol. 2017 Jul;24(7):1811-1820. doi: 10.1245/s10434-017-5797-3. Epub 2017 Feb 10.

19.

Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands.

Jochems A, Schouwenburg MG, Leeneman B, Franken MG, van den Eertwegh AJ, Haanen JB, Gelderblom H, Uyl-de Groot CA, Aarts MJ, van den Berkmortel FW, Blokx WA, Cardous-Ubbink MC, Groenewegen G, de Groot JW, Hospers GA, Kapiteijn E, Koornstra RH, Kruit WH, Louwman MW, Piersma D, van Rijn RS, Ten Tije AJ, Vreugdenhil G, Wouters MW, van der Hoeven JJ.

Eur J Cancer. 2017 Feb;72:156-165. doi: 10.1016/j.ejca.2016.11.021. Epub 2016 Dec 25.

PMID:
28030784
20.

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.

van der Kooij MK, Joosse A, Speetjens FM, Hospers GA, Bisschop C, de Groot JW, Koornstra R, Blank CU, Kapiteijn E.

Acta Oncol. 2017 Jan;56(1):101-103. doi: 10.1080/0284186X.2016.1260773. Epub 2016 Dec 2. No abstract available.

PMID:
27911126
21.

Synthesis and Evaluation of the Estrogen Receptor β-Selective Radioligand 2-18F-Fluoro-6-(6-Hydroxynaphthalen-2-yl)Pyridin-3-ol: Comparison with 16α-18F-Fluoro-17β-Estradiol.

Antunes IF, van Waarde A, Dierckx RA, de Vries EG, Hospers GA, de Vries EF.

J Nucl Med. 2017 Apr;58(4):554-559. doi: 10.2967/jnumed.116.180158. Epub 2016 Dec 1.

22.

Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.

Venema CM, Apollonio G, Hospers GA, Schröder CP, Dierckx RA, de Vries EF, Glaudemans AW.

Clin Nucl Med. 2016 Nov;41(11):844-851. Review.

PMID:
27607175
23.

Retracted: Diagnosis and Treatment of Intestinal Melanoma Metastases in the Era of Effective Systemic Treatment.

Faut M, Bisschop K, Jalving M, Been LB, Noordzij W, Peters FT, van der Leest AH, van Leeuwen BL, Hospers GA.

Ann Surg. 2017 Aug 22. doi: 10.1097/SLA.0000000000001617. [Epub ahead of print] Retraction in: Ann Surg. 2017 Sep 6;:.

PMID:
27140509
24.

Balancing treatment efficacy, toxicity and complication risk in elderly patients with metastatic renal cell carcinoma.

van den Brom RR, van Es SC, Leliveld AM, Gietema JA, Hospers GA, de Jong IJ, de Vries EG, Oosting SF.

Cancer Treat Rev. 2016 May;46:63-72. doi: 10.1016/j.ctrv.2016.04.002. Epub 2016 Apr 16. Review.

25.

Foreign body reaction triggered by cytotoxic T lymphocyte-associated protein 4 blockade 25 years after dermal filler injection.

Bisschop C, Bruijn MS, Stenekes MW, Diercks GF, Hospers GA.

Br J Dermatol. 2016 Dec;175(6):1351-1353. doi: 10.1111/bjd.14674. Epub 2016 Sep 24.

PMID:
27086747
26.

Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.

van den Brom RR, Abdulahad WH, Rutgers A, Kroesen BJ, Roozendaal C, de Groot DJ, Schröder CP, Hospers GA, Brouwer E.

Rheumatology (Oxford). 2016 Jun;55(6):1143-5. doi: 10.1093/rheumatology/kew063. Epub 2016 Apr 11. No abstract available.

PMID:
27069016
27.

Longitudinal analysis of cytokine expression during neoadjuvant chemoradiotherapy and subsequent surgery in esophageal cancer patients.

Bosch DJ, Wang D, Nijsten MW, Mul VE, Hospers GA, Burgerhof JG, Struys MM, Plukker JT.

Am J Surg. 2016 Jul;212(1):89-95. doi: 10.1016/j.amjsurg.2015.12.021. Epub 2016 Feb 27.

PMID:
27036621
28.

Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to Implementation.

van Es SC, Venema CM, Glaudemans AW, Lub-de Hooge MN, Elias SG, Boellaard R, Hospers GA, Schröder CP, de Vries EG.

J Nucl Med. 2016 Feb;57 Suppl 1:96S-104S. doi: 10.2967/jnumed.115.157974. Review.

29.

CD44, SHH and SOX2 as novel biomarkers in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.

Honing J, Pavlov KV, Mul VE, Karrenbeld A, Meijer C, Faiz Z, Smit JK, Hospers GA, Burgerhof JG, Kruyt FA, Kleibeuker JH, Plukker JT.

Radiother Oncol. 2015 Oct;117(1):152-8. doi: 10.1016/j.radonc.2015.08.031. Epub 2015 Sep 10.

PMID:
26364884
30.

Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group.

Lancet Oncol. 2015 Sep;16(9):1090-1098. doi: 10.1016/S1470-2045(15)00040-6. Epub 2015 Aug 5.

PMID:
26254683
31.

Rectal and colon cancer: Not just a different anatomic site.

Tamas K, Walenkamp AM, de Vries EG, van Vugt MA, Beets-Tan RG, van Etten B, de Groot DJ, Hospers GA.

Cancer Treat Rev. 2015 Sep;41(8):671-9. doi: 10.1016/j.ctrv.2015.06.007. Epub 2015 Jun 28. Review.

PMID:
26145760
32.

Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy.

van Kruchten M, Glaudemans AWJM, de Vries EFJ, Schröder CP, de Vries EGE, Hospers GAP.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1674-1681. doi: 10.1007/s00259-015-3107-5. Epub 2015 Jun 20.

33.

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial.

Ayez N, van der Stok EP, de Wilt H, Radema SA, van Hillegersberg R, Roumen RM, Vreugdenhil G, Tanis PJ, Punt CJ, Dejong CH, Jansen RL, Verheul HM, de Jong KP, Hospers GA, Klaase JM, Legdeur MC, van Meerten E, Eskens FA, van der Meer N, van der Holt B, Verhoef C, Grünhagen DJ.

BMC Cancer. 2015 Mar 26;15:180. doi: 10.1186/s12885-015-1199-8.

34.

The value of PET/CT with FES or FDG tracers in metastatic breast cancer: a computer simulation study in ER-positive patients.

Koleva-Kolarova RG, Greuter MJ, van Kruchten M, Vermeulen KM, Feenstra T, Buskens E, Glaudemans AW, de Vries EF, de Vries EG, Hospers GA, de Bock GH.

Br J Cancer. 2015 May 12;112(10):1617-25. doi: 10.1038/bjc.2015.138. Epub 2015 Apr 16.

35.

CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment.

Tamas K, Domanska UM, van Dijk TH, Timmer-Bosscha H, Havenga K, Karrenbeld A, Sluiter WJ, Beukema JC, van Vugt MA, de Vries EG, Hospers GA, Walenkamp AM.

Curr Pharm Des. 2015;21(17):2276-83.

PMID:
25557636
36.

Assessment of estrogen receptor expression in epithelial ovarian cancer patients using 16α-18F-fluoro-17β-estradiol PET/CT.

van Kruchten M, de Vries EF, Arts HJ, Jager NM, Bongaerts AH, Glaudemans AW, Hollema H, de Vries EG, Hospers GA, Reyners AK.

J Nucl Med. 2015 Jan;56(1):50-5. doi: 10.2967/jnumed.114.147579. Epub 2014 Dec 4.

37.

Clinical validation of FDG-PET/CT in the radiation treatment planning for patients with oesophageal cancer.

Muijs CT, Beukema JC, Woutersen D, Mul VE, Berveling MJ, Pruim J, van der Jagt EJ, Hospers GA, Groen H, Plukker JT, Langendijk JA.

Radiother Oncol. 2014 Nov;113(2):188-92. doi: 10.1016/j.radonc.2014.10.016. Epub 2014 Nov 29.

PMID:
25467002
38.

Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.

Falahi F, van Kruchten M, Martinet N, Hospers GA, Rots MG.

Breast Cancer Res. 2014 Jul 29;16(4):412. doi: 10.1186/s13058-014-0412-z. Review.

39.

Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.

van Kruchten M, de Vries EG, Glaudemans AW, van Lanschot MC, van Faassen M, Kema IP, Brown M, Schröder CP, de Vries EF, Hospers GA.

Cancer Discov. 2015 Jan;5(1):72-81. doi: 10.1158/2159-8290.CD-14-0697. Epub 2014 Nov 7.

40.

Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival.

Koen Talsma A, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, van Berge Henegouwen MI, Wijnhoven BP, van Lanschot JJ; CROSS Study Group, Hulshof MC, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW.

Ann Surg. 2014 Nov;260(5):786-92; discussion 792-3. doi: 10.1097/SLA.0000000000000965.

PMID:
25379850
41.

Off-label prescription of genetically modified organism medicines in europe: emerging conflicts of interest?

Schagen FH, Hoeben RC, Hospers GA.

Hum Gene Ther. 2014 Oct;25(10):893-6. doi: 10.1089/hum.2014.090. Review.

PMID:
25268158
42.

Consequence of restaging after neoadjuvant treatment for locally advanced rectal cancer.

Bisschop C, Tjalma JJ, Hospers GA, Van Geldere D, de Groot JW, Wiegman EM, Van't Veer-Ten Kate M, Havenith MG, Vecht J, Beukema JC, Kats-Ugurlu G, Mahesh SV, van Etten B, Havenga K, Burgerhof JG, de Groot DJ, de Vos Tot Nederveen Cappel WH.

Ann Surg Oncol. 2015 Feb;22(2):552-6. doi: 10.1245/s10434-014-3996-8. Epub 2014 Aug 26.

PMID:
25155395
43.

Whole-body PET imaging of breast cancer characteristics to improve precision treatment.

Hospers GA, van Kruchten M, de Vries EG.

Oncology (Williston Park). 2014 May;28(5):434-6. No abstract available.

44.

Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study.

Trip AK, Poppema BJ, van Berge Henegouwen MI, Siemerink E, Beukema JC, Verheij M, Plukker JT, Richel DJ, Hulshof MC, van Sandick JW, Cats A, Jansen EP, Hospers GA.

Radiother Oncol. 2014 Aug;112(2):284-8. doi: 10.1016/j.radonc.2014.05.003. Epub 2014 May 22.

PMID:
24856116
45.

Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.

van den Brom RR, Mäkelburg AB, Schröder CP, de Vries EG, Hospers GA.

J Clin Oncol. 2015 Dec 20;33(36):e133-4. doi: 10.1200/JCO.2013.51.4471. Epub 2014 Apr 28. Review. No abstract available.

PMID:
24778390
46.

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

Kelderman S, Heemskerk B, van Tinteren H, van den Brom RR, Hospers GA, van den Eertwegh AJ, Kapiteijn EW, de Groot JW, Soetekouw P, Jansen RL, Fiets E, Furness AJ, Renn A, Krzystanek M, Szallasi Z, Lorigan P, Gore ME, Schumacher TN, Haanen JB, Larkin JM, Blank CU.

Cancer Immunol Immunother. 2014 May;63(5):449-58. doi: 10.1007/s00262-014-1528-9. Epub 2014 Mar 8.

PMID:
24609989
47.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

Larkin J, Del Vecchio M, Ascierto PA, Krajsova I, Schachter J, Neyns B, Espinosa E, Garbe C, Sileni VC, Gogas H, Miller WH Jr, Mandalà M, Hospers GA, Arance A, Queirolo P, Hauschild A, Brown MP, Mitchell L, Veronese L, Blank CU.

Lancet Oncol. 2014 Apr;15(4):436-44. doi: 10.1016/S1470-2045(14)70051-8. Epub 2014 Feb 27.

PMID:
24582505
48.

Increased risk of thromboembolism in esophageal cancer patients treated with neoadjuvant chemoradiotherapy.

Bosch DJ, Van Dalfsen QA, Mul VE, Hospers GA, Plukker JT.

Am J Surg. 2014 Aug;208(2):215-21. doi: 10.1016/j.amjsurg.2013.10.031. Epub 2014 Jan 23.

PMID:
24534559
49.

A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients.

Honing J, Smit JK, Muijs CT, Burgerhof JG, de Groot JW, Paardekooper G, Muller K, Woutersen D, Legdeur MJ, Fiets WE, Slot A, Beukema JC, Plukker JT, Hospers GA.

Ann Oncol. 2014 Mar;25(3):638-43. doi: 10.1093/annonc/mdt589. Epub 2014 Feb 2.

50.

Impact of neoadjuvant chemoradiotherapy on postoperative course after curative-intent transthoracic esophagectomy in esophageal cancer patients.

Bosch DJ, Muijs CT, Mul VE, Beukema JC, Hospers GA, Burgerhof JG, Plukker JT.

Ann Surg Oncol. 2014 Feb;21(2):605-11. doi: 10.1245/s10434-013-3316-8. Epub 2013 Oct 8.

PMID:
24100962

Supplemental Content

Loading ...
Support Center